GlassScriptPhysician profile
Basanagoud D Mudigoudar
NPI 1528278223
$2,348.00
in general payments reported to CMS, 2019-2025
15 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,169 · 2020: $13.18 · 2021: $12.25 · 2022: $177 · 2023: $313 · 2024: $407 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $976.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Monteris Medical Corporation | $963.10 | 2019 | |
| Ucb, INC. | $453.04 | 2020-2025 | Briviact, Fintepla, Nayzilam |
| Neuropace, INC. | $319.70 | 2019-2023 | |
| Livanova USA, INC. | $156.31 | 2019 | |
| Neurelis, INC. | $155.59 | 2023-2025 | Valtoco |
| Itf Therapeutics LLC | $63.42 | 2024 | |
| Sk Life Science, INC. | $51.86 | 2023-2024 | |
| Azurity Pharmaceuticals, INC. | $45.48 | 2025 | Zonisade |
| Acadia Pharmaceuticals INC | $37.78 | 2023-2025 | Daybue |
| Jazz Pharmaceuticals INC. | $24.98 | 2024 | |
| Immedica Pharma US, INC. | $24.00 | 2024 | |
| Upsher-Smith Laboratories LLC | $22.88 | 2025 | |
| Eisai INC. | $17.61 | 2022 | |
| Aquestive Therapeutics, INC. | $12.25 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basanagoud Mudigoudar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.